(CercleFinance.com) – OSE Immuno announced on Thursday that it had treated a first patient with its anti-PD1 monoclonal antibody as part of the start of a phase 1/2 trial devoted to solid tumors or advanced lymphomas.
This first clinical study by the French biotech aims to determine the maximum tolerated dose and/or the recommended dose in phase 2 of OSE-279 as monotherapy in the two indications.
Secondary objectives include evaluation of antitumor activity, safety profile, pharmacokinetics and receptor occupancy or pharmacodynamic profile.
OSE-279 is a humanized monoclonal antibody that blocks both PD-L1 and PD-L2 proteins, the overexpression of which represents a tumor escape mechanism to the immune response.